

## Vascular Medicine Twitter Journal Club Agenda

**When:** Tuesday, November 15, @ 8-9 pm EST

**Where:** The discussion takes place on Twitter. Click on [@VMJ SVM](#) or search for [#VascMedJC](#) on Twitter.

**Facilitator:** Alec Schmaier ([@ASchmaier](#)), Social Media Editor for *Vascular Medicine*

### Article to be discussed

#### Improvement in walking impairment following surgical and endovascular revascularization: Insights from VOYAGER PAD

Shea E Hogan, Mark R Nehler, Sonia Anand, Manesh R Patel, Sebastian Debus, Matthew T Jackson, Cullen Buchanan, R Wilson King, Connie Hess, Eva Muehlhofer, Lloyd P Haskell, Rupert M Bauersachs, Scott D Berkowitz, Judith Hsia, and Marc P Bonaca

[\[Download article\]](#)

### Planned Discussion Questions

1. #VascMedJC Q1: What were the key findings of this study?  
[@SheaHogan7](#) [@DrSoniaAnand1](#) [@MarcBonaca](#) [@cpcresearch](#)
2. #VascMedJC Q2: This study used the WIQ questionnaire. How can we better incorporate this or other assessments of walking impairment into clinical practice?
3. #VascMedJC Q3: At what threshold of walking dysfunction do you typically recommend lower extremity revascularization for patients with PAD?
4. #VascMedJC Q4: Why may patients still be symptomatic after successful lower extremity revascularization?

### Instructions

- Please use the hashtag #VascMedJC on all tweets
- When responding to a tweet, choose retweet with comment/quote tweet (don't just directly reply)
- Complete details and instructions: <https://www.vascularmed.org/i4a/pages/index.cfm?pageid=3510>

### Disclaimer

Statements and opinions expressed during the *Vascular Medicine* journal club do not necessarily represent the position of the Society for Vascular Medicine.

### Authors' Acknowledgment

This work would not have been possible without Dr William Hiatt's pioneering contributions to the medical community's knowledge of PAD pathophysiology and management. Thank you, Dr Hiatt—you are remembered and greatly missed.

### Declaration of Conflicting Interests

The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: The following authors receive salary support from CPC through funds transferred to the University of Colorado: Dr Hogan, Dr Jackson, Dr Nehler, Dr Hess, Dr Berkowitz, Dr Hsia, and Dr Bonaca. CPC, a nonprofit academic research organization affiliated with the University of Colorado, receives research funding from: Abbott, Agios, Alexion Pharma, Alnylam, Amgen, Angionetics, ARCA Biopharma, Array, AstraZeneca, Atentiv, Audentes, Bayer, Better Therapeutics, Brigham and Women's Hospital, Bristol Myers Squibb, Cardiol Therapeutics, CellResearch, Cook Medical, Cook, CSL Behring, Eidos Therapeutics, EP Trading Co, Esperion Therapeutics, EverlyWell, Faraday, Fortress Biotech, DHL Therapeutics, HeartFlow, Hummingbird Bioscience, Insmad, Janssen, Kowa Research, Lexicon, Merk, Medtronic, Moderna, Novate Medical, Novo Nordisk, Pfizer, PhasBio, PPD Development, Prarie Education and Research, Prothena Ciosciences, Regeneron, Regio Biosciences, Sanafit Therapeutics, Sanofi, Smith and Nephew, Stealth Bio-Therapeutics, University of

Colorado, Worldwide Clinical Trials, Wraser, Yale Cardiovascular Research Group. Dr Buchanan reports no disclosures. Dr King receives support from the American Heart Association Strategically Focused Research Network in Vascular Disease under award number 18SFRN3390085 (BWH-DH SFRN Center). Dr Anand reports receiving lecture fees from Bayer and Janssen. Dr Patel reports receiving grant support, advisory board fees, and consulting fees from AstraZeneca, Bayer, and Janssen, grant support from Medtronic and Philips Healthcare, and grant support and advisory board fees from HeartFlow. Dr Debus reports receiving grant support from Cook and Terumo Aortic. Dr Muehlhofer reports being employed by Bayer. Dr Haskell reports being employed full time by Janssen Pharmaceuticals, LLC. Dr Bauersachs reports receiving consulting fees and lecture fees from Bayer, Bristol Myers Squibb, and Pfizer. Dr Berkowitz was employed as a clinical research physician by Bayer at the time VOYAGER PAD was performed. Dr Bonaca is the Executive Director of CPC (see above) and receives grant support from Amgen, AstraZeneca, Merck, Novo Nordisk, Pfizer, and Sanofi and support from the AHA SFRN under award numbers 18SFRN3390085 (BWH-DH SFRN Center) and 18SFRN33960262 (BWH-DH Clinical Project). Dr Bonaca also reports stock in Medtronic and Pfizer and consulting fees from Audentes.

### **Funding**

The VOYAGER PAD trial was supported by a grant from Bayer AG and Janssen Research & Development, LLC. Dr Anand receives lecture fees from Bayer. Dr Patel receives grant support, advisory board fees, and consulting fees from Bayer. Dr Muehlhofer is employed by Bayer. Dr Bauersachs receives consulting fees and lecture fees from Bayer. Dr Berkowitz was employed as a clinical research physician by Bayer at the time VOYAGER PAD was performed.